Internal Reference Number: FOI_9562
Date Request Received: 21/07/2026 00:00:00
Date Request Replied To: 07/08/2026 00:00:00
This response was sent via: By Email
Request Summary: Dermatology Services
Request Category: Companies
| Question Number 1: I am writing to submit a new FOI request about dermatology services at your NHS organisation. In the last 6 months (November 2025 to April 2026), how many adult patients were treated by the dermatology department, excluding patients referred for cancer/suspected cancer? | |
| Answer To Question 1: Please see our response to Q1,3,4 and 5 in the spreadsheet attached. To accompany this answer to question 1 please also see the documents listed below:  13893 - FOI_9562 - Dermatology Services.xlsx | |
| Question Number 2: Do you run a specific clinic for patients with atopic dermatitis? | |
| Answer To Question 2: The Trust do not have a specific clinic for AD, patients are seen in all our Consultant led dermatology clinics with every other inflammatory skin disease and when we treat them in our treatment centre it is not specified. | |
| Question Number 3: In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were treated by the dermatology department? | |
| Answer To Question 3: Please see our response to Q1,3,4 and 5 in the spreadsheet attached. | |
| Question Number 4: In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were treated with the following products: a. Immunosuppressants (Azathioprine, Ciclosporin, Methotrexate, Mycophenolate mofetil, Pimecrolimus, or Tacrolimus) b. Abrocitinib c. Baricitinib d. Dupilumab e. Lebrikizumab f. Tralokinumab g. Upadacitinib h. Nemolizumab i. Delgocitinib | |
| Answer To Question 4: Please see our response to Q1,3,4 and 5 in the spreadsheet attached. | |
| Question Number 5: In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were started on the following products: a. Immunosuppressants (Azathioprine, Ciclosporin, Methotrexate, Mycophenolate mofetil, Pimecrolimus, or Tacrolimus) b. Abrocitinib c. Baricitinib d. Dupilumab e. Lebrikizumab f. Tralokinumab g. Upadacitinib h. Nemolizumab i. Delgocitinib | |
| Answer To Question 5: Please see our response to Q1,3,4 and 5 in the spreadsheet attached. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
